Phase classification • Trial termination
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CA6 (Carbonic Anhydrase 6)
|
CXCR4 mutation • MYD88 mutation + CXCR4 mutation
|
Imbruvica (ibrutinib) • ulocuplumab (BMS-936564)